Top-News
Pharmazeutika Israel

Galmed Pharmaceuticals Ltd News

Aktie
WKN:  A1XFUX ISIN:  IL0011313900 US-Symbol:  GLMD
0,388 €
+0,029 €
+8,08%
22:53:56 Uhr
Handeln Depot/Watchlist
Aktienanzahl *
3,81 Mio.
Marktkapitalisierung *
1,36 Mio. €
Streubesitz
-
Index-Zugehörigkeit
-
IR-Website
zur Website
*Stand: 10.04.2024

Galmed Pharmaceuticals Ltd News

04.04.24 - PR Newswire
Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2023
Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2023 PR Newswire
15.03.24 - PR Newswire
Galmed Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of NASH and Liver Fibrosis
Galmed Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of NASH and Liver Fibrosis PR Newswire
20.11.23 - PR Newswire
Galmed Announces a delay in the initiation of its Primary Sclerosing Cholangitis (PSC) Phase 2a Study
Galmed Announces a delay in the initiation of its Primary Sclerosing Cholangitis (PSC) Phase 2a Study PR Newswire
26.09.23 - PR Newswire
Galmed Announces Allowance of New Patent for Aramchol for the Treatment of Pulmonary and Dermal Fibrosis
Galmed Announces Allowance of New Patent for Aramchol for the Treatment of Pulmonary and Dermal Fibrosis PR Newswire
22.09.23 - PR Newswire
Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification
Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification PR Newswire
14.07.23 - PR Newswire
Galmed Pharmaceuticals Announces Pricing of $7 Million Public Offering
Galmed Pharmaceuticals Announces Pricing of $7 Million Public Offering PR Newswire
13.07.23 - PR Newswire
Thinking about buying stock in Healthcare Triangle, Galmed Pharmaceuticals, Express, Kartoon Studios, or Aeroports de Paris?
Thinking about buying stock in Healthcare Triangle, Galmed Pharmaceuticals, Express, Kartoon Studios, or Aeroports de Paris? PR Newswire
10.07.23 - PR Newswire
Galmed to employ OnKai's disruptive Artificial Intelligence (AI) in its Planned Phase 2a Clinical Trial in PSC
Galmed to employ OnKai's disruptive Artificial Intelligence (AI) in its Planned Phase 2a Clinical Trial in PSC PR Newswire
01.06.23 - PR Newswire
Galmed Pharmaceuticals Reports First Quarter 2023 Financial Results and Recent Developments
Galmed Pharmaceuticals Reports First Quarter 2023 Financial Results and Recent Developments PR Newswire
09.05.23 - PR Newswire
Galmed Announces Initiation of a Clinical Development Program to Evaluate Aramchol meglumine for the Treatment of Primary Sclerosing Cholangitis (PSC)
Galmed Announces Initiation of a Clinical Development Program to Evaluate Aramchol meglumine for the Treatment of Primary Sclerosing Cholangitis (PSC) PR Newswire
29.03.23 - PR Newswire
Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2022
Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2022 PR Newswire
08.02.23 - PR Newswire
Galmed Announces Issuance of New Composition of Matter Patent for Aramchol meglumine Salt
Galmed Announces Issuance of New Composition of Matter Patent for Aramchol meglumine Salt PR Newswire
14.12.22 - PR Newswire
Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) Announces Receipt of Extension to Meet the Nasdaq's Minimum Bid Price Requirement
Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) Announces Receipt of Extension to Meet the Nasdaq's Minimum Bid Price Requirement PR Newswire
04.08.22 - PR Newswire
Galmed Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Financial Results
Galmed Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Financial Results PR Newswire
07.07.22 - PR Newswire
Galmed Reports Significant Anti-Fibrotic Effects of Aramchol in a Lung Fibrosis Model
Galmed Reports Significant Anti-​Fibrotic Effects of Aramchol in a Lung Fibrosis Model PR Newswire
31.10.19 - PR Newswire
Galmed Pharmaceuticals to Present New Data on Aramchol Effect on Glucose Metabolism, MoA and Clinical Results at AASLD 2019
Galmed Pharmaceuticals to Present New Data on Aramchol Effect on Glucose Metabolism, MoA and Clinical Results at AASLD 2019 PR Newswire
09.04.19 - PR Newswire
Galmed Pharmaceuticals Announces Successful Completion of End of Phase 2 Meeting With FDA and Plan for Start of Phase 3
Galmed Pharmaceuticals Announces Successful Completion of End of Phase 2 Meeting With FDA and Plan for Start of Phase 3 PR Newswire
09.05.18 - PR Newswire
Galmed Pharmaceuticals Provides Business Update and Reports First Quarter 2018 Financial Results
Galmed Pharmaceuticals Provides Business Update and Reports First Quarter 2018 Financial Results - Conference Call and Webcast Today at 8:30 a.m. EST / 5:30 a.m. PST - PR ...
27.03.18 - PR Newswire
Galmed Pharmaceuticals to Present New Scientific Data on the Mechanism by Which Aramchol Exerts its Effect on Fibrosis at EASL
Galmed Pharmaceuticals to Present New Scientific Data on the Mechanism by Which Aramchol Exerts its Effect on Fibrosis at EASL PR Newswire
07.11.17 - PR Newswire
Galmed Pharmaceuticals to Provide Corporate Overview at the Stifel 2017 Healthcare Conference
Galmed Pharmaceuticals to Provide Corporate Overview at the Stifel 2017 Healthcare Conference PR Newswire

Newssuche

Videos

newspaper
08:55 Uhr +6,89%
Technical Trading: Rohöl Short Chance
Rohöl Short Typ: Turbo Open End WKN: VD4JF9 Hebel: 13 Laufzeit: OpenEnd Einstieg: Market ... Mehr »